Menveo FDA Approval History
FDA Approved: Yes (First approved February 19, 2010)
Brand name: Menveo
Generic name: meningococcal conjugate vaccine
Company: Novartis Vaccines and Diagnostics
Treatment for: Meningococcal Meningitis Prophylaxis
Menveo (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine) is a vaccine indicated for active immunization to prevent invasive meningococcal disease caused by Neisseria meningitidis serogroups A, C, Y and W-135.
Development Timeline for Menveo
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.